Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


ROCHE DIAGNOSTICS TO SELL EXIQON´S PROBELIBRARY REAL-TIME PCR ASSAYS
Test kits ensure detection of virtually any gene of a certain cell


Roche Diagnostics and Exiqon, Vedbæk, Denmark, a provider of high-value gene expression analysis products, today announced the signing of an agreement naming Roche Diagnostics as sole distributor of Exiqon’s ProbeLibrary Kits. ProbeLibrary products are innovative kits for gene expression analysis and target validation of microarray experiments using real-time PCR. ProbeLibrary Kits ensure the detection of virtually any gene of a certain cell. Unique features of the kits include day-to-day assay availability and the free web-based ProbeFinder software package. The ProbeLibrary was launched in May 2004 and now provides potential for the design of over 2.5 million assays in seven organisms. Financial details of the agreement were not disclosed.

“The ProbeLibrary concept addresses the current need for increased speed and flexibility in biomedical research and complements our extensive portfolio of Real-time PCR products in the best possible way,” comments Volker Pfahlert, Head of Roche Applied Science, a business area within Roche Diagnostics. “One of the key factors in our decision has been the very positive feedback from existing customers.
This agreement further strengthens the already strong position Roche Diagnostics has in the rapidly growing Real-time PCR market. Furthermore, it is a step in completing our high-throughput product portfolio. Another important step will be the launch of the LightCycler™ 480 in the second half of 2005. ”

“Roche Diagnostics is one of the top players in the real-time PCR market and this license and distribution agreement underlines our position as a leading supplier of innovative research products”, says Exiqon’s President and CEO Lars Kongsbak, and continues “This is an important milestone for Exiqon. With the product focus and the extensive sales and marketing capabilities of the Roche Diagnostics team, we consider this strategically the optimal placement of our ProbeLibrary product. This agreement allows us to focus all attention on our next product launch.”

ProbeLibrary Kits ensure the detection of virtually any gene of a certain cell based on only 90 detection probes. The ProbeLibrary format is compatible with the existing over 17000 installed real-time PCR detection instruments currently on the market. More information and the assay design software can be found at www.probelibrary.com.

About PCR
The polymerase chain reaction (PCR) is a nucleic acid amplification technology that allows minute amounts of genetic material to be amplified into billions of copies in just a few hours. It has enabled many significant advances in the Human Genome project, DNA fingerprinting, and in the diagnosis and monitoring of diseases such as AIDS and hepatitis.

Since first acquiring the rights to PCR technology in 1991, Roche has become a global leader in the development and marketing of PCR-based technologies. Roche’s passionate pursuit of PCR innovation and automation has created a new standard that will continue to evolve as a major force in improving healthcare. Roche’s real-time PCR technology provides superior assay performance, with broad dynamic ranges and excellent sensitivity and specificity.

Real-time PCR is an extension to the basic PCR method where the amount of amplified target is measured in real time during the amplification phase, thereby enabling instant quantification of the target. This has become the method of choice for low to medium throughput gene expression monitoring and target validation. The market for Real-time PCR is one of the fastest growing segments within the research reagent market.

About Roche and the Roche Diagnostics Division
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fro


Publisher Contact Information:

Exiqon A/S
+45 (45) 66 08 88
sme@exiqon.com

Company profile of Exiqon A/S
Past press releases of Exiqon A/S.

Data


26,129
Tech investments
From our Online Data Service
16,883
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 13N/AEnergy related
Sep 13€12.6MConsumer electronics
Sep 12€39.0MBiopharmaceuticals
Sep 12N/AKnowledge management
Sep 12€2.3MInternet commerce
Sep 12€2.1MInternet services
Sep 12€4.0MMedical devices

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.